Viva Biotech Holdings (VBIZF)
- Previous Close
0.0500 - Open
0.0500 - Bid --
- Ask --
- Day's Range
0.0500 - 0.0500 - 52 Week Range
0.0500 - 0.2319 - Volume
500 - Avg. Volume
72 - Market Cap (intraday)
153.222M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2021
- 1y Target Est
--
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure analysis of protein, and SPR technology; and PROTAC/molecular glue services. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. Viva Biotech Holdings was incorporated in 2008 and is headquartered in Shanghai, China.
www.vivabiotech.com.cnRecent News: VBIZF
Performance Overview: VBIZF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VBIZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VBIZF
Valuation Measures
Market Cap
153.22M
Enterprise Value
272.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
0.21
Enterprise Value/Revenue
0.13
Enterprise Value/EBITDA
2.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.39%
Return on Assets (ttm)
1.57%
Return on Equity (ttm)
-2.74%
Revenue (ttm)
2.16B
Net Income Avi to Common (ttm)
-116.11M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.04B
Total Debt/Equity (mrq)
51.61%
Levered Free Cash Flow (ttm)
--
Company Insights: VBIZF
VBIZF does not have Company Insights